<DOC>
	<DOCNO>NCT02413021</DOCNO>
	<brief_summary>The purpose study determine whether deferasirox effective treatment acute lymphatic leukemia ( ALL ) acute Myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>The Effect Deferasirox Response Rate Acute Leukemia Patients Not Treated Standard Chemotherapy Regimens</brief_title>
	<detailed_description>Many study demonstrate Iron essential metabolism , cell cycle regulation metastasis different cancer cell line . It also believe Iron concentration increase cancer cell enhance expression TFR-1 receptor case receptor saturation , non-receptor-mediated pinocytosis would significant pathway iron intake . Iron deficiency may lead increase P 53 consequently stop cell mitosis G1-S state . It also increase expression N-myc down-regulated gene 1 suppress metastasis cancer . It suggest Iron chelators may decrease leukemic tumor growth animal model acute myeloid leukemia ( AML ) . Some case study demonstrate role Iron chelators relapse and/or refractory AML . Finally phase 1 clinical study undertaken evaluate role Tiapine cytarabine adult AML high-risk myelodysplastic syndrome . So study investigator try evaluate role iron chelate agent ( deferasirox ) patient acute lymphatic leukemia ( ALL ) AML patient treat standard chemotherapy regime .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>1 . Patients acute leukemia ( myeloid lymphoblastic ) receive standard chemotherapy regimens treatment ; follow reason : 1. age &gt; 65 2. existence another illness , heart failure ( EF &gt; 40 ) 2 . Ferritin &lt; 500 μg / l 3 . Not existence co morbidity 4 . GFR &gt; 40 1 . GFR &lt; 40 2 . Control group become iron overload ( Ferritin &gt; 500 μg /l ) 3 . Incidence severe gastrointestinal symptom ( Mucositis , Enterocolitis , Typhlitis , Nausea , Diarrhea ) 4 . Not willing continue treatment .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoid Leukemia</keyword>
	<keyword>deferasirox</keyword>
</DOC>